Lawsuit Filed Against Copley Over Albuterol

16 January 1995

A lawsuit has been filed in the USA against Copley Pharmaceuticals, a subsidiary of Hoechst, claiming that contamination of its asthma medication albuterol with the bacterium Pseudomonas flourescens caused the death of 40 people, including eight children.

The suit is for $100 million in punitive damages, plus actual damages. The claim is the biggest outside the Federal Court where a class action suit based on more than 36 suits is pending.

Albuterol was withdrawn from sale in January last year after contamination of the product with the bacterium, a generally benign strain found in tap water, was discovered.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight